Figure 3 | Scientific Reports

Figure 3

From: Impact of polymyxin B hemoperfusion therapy on high endotoxin activity level patients after successful infection source control: a prospective cohort study

Figure 3

The comparison of changes in EA level with SD by period according to the conductance of PMX-HP or not. With PMX-HP treatment, difference of EA level showed significant time-by-group interactions in both high risk group (A, F = 7.56, p = 0.003) and low risk group (B, F = 10.58, p < 0.001). C, changes of SOFA scores with SD in patients who received PMX-HP treatment. The high risk group (blue, EA at T0 ≥ 0.54) showed continuous improvements in SOFA scores, whereas no improvements were revealed in the low risk group (gray, EA at T0 < 0.54). *p < 0.05 vs. baseline (T0); **p < 0.01 vs. baseline (T0). EA endotoxin activity, PMX-HP polymyxin B-hemoperfusion, SD standard deviation, SOFA Sequential Organ Failure Assessment, EA endotoxin activity PMX-HP polymyxin B-hemoperfusion, SOFA Sequential Organ Failure Assessment.

Back to article page